Preclinical Toxicology Study Shows Excellent Results On Countervail’s Lead Antidote Candidate January 2, 2018 • admin • Funding, General News, Grants, Pharmaceuticals Read More »
Data from two relevant animal models presented at the 2017 CounterACT meeting by Countervail CEO June 16, 2017 • admin • General News, Military, Pharmaceuticals Read More »
FDA agrees that Countervail’s non-human primate animal model is appropriate for the company’s Animal Rule pivotal GLP study testing February 15, 2017 • admin • General News, Pharmaceuticals, Regulatory Read More »
Israeli parent patent for the use of Galantamine and Antimuscarinic Agent For Organophosphorus Poisoning awarded. February 21, 2016 • admin • General News, Military, Pharmaceuticals Read More »
Canadian parent patent and CIP for the use of galantamine as a Method of Treating Organophosphorus Poisoning awarded. October 27, 2015 • admin • General News Read More »
Countervail competes and is selected for participation in the SBIR sponsored Commercialization Acceleration Program (CAP). October 14, 2015 • admin • Funding, General News Read More »
Countervail receives additional $630,000 SBIR Fast Track Phase II grant award for continued development of AverTox® (galantamine) for pre-exposure administration to protect against soman toxicity. August 3, 2015 • admin • Funding, General News Read More »
US Patent application submitted for novel OP Exposure Diagnostic Test. June 23, 2015 • admin • General News, Pharmaceuticals Read More »
Countervail receives additional $845,000 SBIR Fast Track Phase II grant award for continued development of AverTox® (galantamine) for pre-exposure administration to protect against soman toxicity. May 29, 2015 • admin • Funding, General News, Military, Pharmaceuticals, Uncategorized Read More »
Countervail holds second pre-IND meeting with Neurology Division of the FDA for guidance on development of a neuroprotectant against nerve agent exposure. February 20, 2015 • admin • General News, Pharmaceuticals Read More »